1

1 Title page

2 From Past to Present: Pompe Disease, Pseudodeficiency Alleles, and Diagnostic Challenges

- 3 Florencia Giliberto^{1,2}, Paula Inés Buonfiglio³, Gabriel Capellino⁴, Carmen Llames Massini^{1,2},
- 4 Viviana Dalamón³, Leonela Luce^{1,2,5}, Micaela Carcione^{1,2}
- 5 ¹Laboratorio de Distrofinopatías, Cátedra de Genética, Facultad de Farmacia y Bioquímica,
- 6 Universidad de Buenos Aires, Buenos Aires, Argentina.
- 7 ²Instituto de Inmunología, Genética y Metabolismo (INIGEM), UBA-CONICET-Hospital de
- 8 Clínicas "José de San Martín", Buenos Aires, Argentina.
- 9 ³Laboratorio de Fisiología y Genética de la Audición. Instituto de Investigaciones en
- 10 Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres" (INGEBI-CONICET).
- 11 ⁴Centro Médico ROENTGEN.
- ⁵John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research
- 13 Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle
- 14 upon Tyne, United Kingdom
- 15 Corresponding Author:
- 16 Prof. PhD. Florencia Giliberto
- 17 Universidad de Buenos Aires
- 18 Departamento de Microbiología, Inmunología, Biotecnología y Genética
- 19 Buenos Aires, Argentina
- 20 gilibertoflor@gmail.com

²¹

2

22 Keywords: POMPE, PSEUDODEFICIENCY, DIAGNOSTIC, OCULOPHARYNGEAL MUSCULAR

- 23 DYSTROPHY, GENETIC VARIANTS and NEUROMUSCULAR DISORDERS.
- 24 Funding
- 25 This study was supported by grants from the University of Buenos Aires (UBACYT: UBACyT
- 26 2020-No20020190100332BA).
- 27

Graphical abstract

From Past to Present: Pompe Disease, Pseudodeficiency Alleles, and Diagnostic Challenges



4

32 Abstract

33 Pompe disease is an autosomal recessive disorder caused by GAA variants leading to acid 34 alpha-glucosidase deficiency. Diagnosis is challenging due to the variable phenotypic 35 presentation and overlap with other conditions. Traditionally, diagnosis relies on measuring 36 enzyme activity, but next-generation sequencing (NGS) advancements have improved 37 accuracy. However, interpreting variants is complex, especially because pseudodeficiency 38 alleles mimic disease-causing variants. We present two patients harboring the 39 pseudodeficiency allele NM 000152.5(GAA):c.271G>A, p.Asp91Asn, which is confusing due 40 to inaccurate reports and results related to enzymatic activity. The first case was a recently 41 published controversial case of a 700-year-old mummy in which the authors classified the 42 variant as pathogenic. The second patient had symptoms compatible with late-onset Pompe 43 disease and was homozygous for the variant. We aimed to determine the correct variant 44 classification using GAA:c.271G>A as a model and to achieve a genetic diagnosis of the second 45 patient. This variant was analyzed following international guidelines (ACMG-AMP) and 46 reviewed with the Lysosomal Diseases Variant Curation Expert Panel. The second patient 47 underwent NGS. We demonstrated that GAA:c.271G>A meets the criterion of being classified 48 as benign for Pompe. Additionally, the second patient carried a heterozygous pathogenic 49 PABPN1 variant associated with oculopharyngeal muscular dystrophy, which better explained 50 the clinical features. This underscores the importance of expanding the genetic analysis in the 51 presence of pseudodeficiency alleles that can mask the true cause of the disease and 52 highlights the fact that an accurate diagnosis should adhere to guidelines on variant curation 53 to reduce the risk of misdiagnosis, which could result in inadequate care and risky medical 54 decisions.

5

56 Introduction

57 Pompe disease, also named glycogen storage disease type II or acid maltase deficiency, is a 58 rare genetic disorder with an autosomal recessive inheritance pattern. Globally, the 59 prevalence of this disease is estimated to be between 5,000 and 10,000 people, with an 60 incidence of 1 in 57,000 people for the late-onset form [1]. Pompe disease is caused by 61 alterations in the GAA gene, leading to a deficiency of acid alpha-glucosidase, a crucial 62 lysosomal enzyme for degrading glycogen [2–4]. Its deficiency causes glycogen accumulation 63 in lysosomes, leading to progressive cellular dysfunction and cell death. It primarily affects 64 neurons and skeletal, smooth and cardiac muscles, resulting in muscle function impairment 65 and progressive and irreversible deterioration [5].

66 Pompe disease exhibits significant clinical heterogeneity, variation is based on the age of 67 onset and symptoms progression. Residual acid alpha-glucosidase activity determines the 68 onset of the disease. Infantile-onset Pompe disease (IOPD) is the most severe form of the 69 disease and occurs when the enzyme activity is less than 1%, conversely, late-onset Pompe 70 disease (LOPD) occurs when the residual enzyme activity ranges between 2% and 30% [4]. 71 Symptoms of IOPD include progressive muscle weakness, hypotonia since birth, severe 72 respiratory problems, hypertrophic cardiomyopathy, and hepatomegaly. Patients also often 73 experience delays in motor development, such as difficulties in sitting, crawling, or walking 74 [2,5]. However, symptoms in LOPD patients can have a juvenile or adult onset, and patients 75 tend to develop symptoms more slowly than IOPD patients. Patients may present progressive 76 muscle weakness, respiratory problems that worsen in advanced stages, muscle pain, fatigue, 77 and difficulty in walking. Muscle atrophy and proximal weakness are also common features 78 of [1]. this disease

6

79 The type of molecular alteration and its location in the GAA gene often predict the clinical 80 phenotype of Pompe disease [6]. To date, more than 300 alterations in GAA have been 81 described [2–4]. Most (96%) of them are single nucleotide variants (SNVs), while only 4% are 82 copy number variants (CNVs). Therefore, sequencing is the ideal strategy for executing the 83 GAA genetic diagnostic algorithm [7,8]. The measurement of acid alpha-glucosidase activity in dried blood spots was traditionally the 84 primary method for diagnosing Pompe disease. In recent years, the advances and 85 86 popularization of NGS technologies have led to a paradigm shift toward genetic/molecular 87 diagnosis. To reduce arbitrariness in the classification of identified sequence variants, the 88 American College of Medical Genetics and Genomics (ACMG) and the Association for 89 Molecular Pathology (AMP) have developed international consensus guidelines to estimate a 90 score based on collected evidence that allows variant classification into one of five possible 91 categories: pathogenic (\geq 10), likely pathogenic (6 to 9), uncertain significance (0 to 5), likely 92 benign (-1 to -6), or benign (\leq -7) [9]. Current recommendations indicate that the diagnosis of 93 Pompe disease should be established when both a deficit of acid alpha-glucosidase enzyme 94 and two pathogenic *trans* variants in the GAA gene are detected [10]. Accurate and early 95 diagnosis of Pompe disease is even more relevant now that an enzyme replacement therapy 96 for treating these patients has been approved [11,12].

97 It should be noted that diagnosing Pompe disease can be challenging. Clinically speaking, the 98 variable presentation of the disease and the symptoms overlap with other conditions and 99 often delay diagnosis. Additionally, the interpretation of *GAA* variants can be complex, 100 especially in the presence of pseudodeficiency alleles, which can mimic disease-causing 101 variants. The main difficulty lies in the fact that pseudodeficiency alleles exhibit low acid

102 alpha-glucosidase enzyme activity in *in vitro* tests, which can be indistinguishable from the 103 pathological deficiency observed in these tests [13]. Therefore, additional biochemical analyses are required to distinguish between true enzyme deficiency leading to Pompe 104 105 disease and pseudodeficiency alleles that have no clinical impact [10]. To facilitate variant 106 interpretation, the ClinGen Lysosomal Diseases Variant Curation Expert Panel recently 107 adapted the ACMG-AMP guidelines for the classification of molecular alterations involved in 108 metabolic storage diseases and the development of specific criteria for the analysis of GAA 109 variants [14].

110 Here, we present in which the pseudodeficiency allele two cases 111 NM 000152.5(GAA):c.271G>A, p.Asp91Asn, also known as GAA2, was identified. The first is 112 a controversial case of a 700-year-old mummy published in 2021, where the authors classified 113 the change as pathogenic and as an LOPD case, confusing the interpretation of the variant 114 within the scientific community [15]. The second patient referred to our laboratory was 115 clinically suspected of presenting LOPD. We demonstrated the importance of adhering to 116 international guidelines for accurate classification of variants that follow Mendelian 117 inheritance using this pseudodeficiency allele as a model. Finally, our goal was to achieve a 118 definitive and accurate diagnosis of the second patient, underscoring the critical role of 119 precise genetic diagnosis in guiding appropriate clinical management.

- 120 Materials and Methods
- 121 Patient

122 The patient, hereafter called "Case 2", was referred by a neurologist to the 123 Dystrophinopathies Laboratory (INIGEM, UBA-CONICET-Hospital de Clínicas "José de San 124 Martín") with a clinical suspicion of Pompe disease. Muscle strength was evaluated manually

8

125 using the Medical Research Council (MRC) scale [16]. Alpha-glucosidase activity was 126 measured from dried blood spots, with reference values between 2.10 and 29.00 µmol/L/h. 127 The protocol was approved by the Institutional Review Board. Informed consent was obtained 128 from the study subjects prior to the molecular studies. 129 Samples and NGS Sequencing 130 Genomic DNA (gDNA) was extracted from peripheral blood lymphocytes of patient 2 following 131 the cetyltrimethylammonium bromide (CTAB) protocol [17]. Then, whole exome sequencing 132 (WES) was performed using the Illumina NovaSeq Sequencing Platform and the Agilent 133 SureSelect V6-post as a capture kit (coverage>20X: 91.7%; Macrogen Service, Korea). Aligned 134 reads were compared to the human reference genome assembly GRCh38. WES results were 135 filtered by an *in silico* panel that included the approximately 700 genes described in the work 136 titled "The 2024 version of the gene table of neuromuscular disorders (nuclear genome)" [18]. Variant filtering and analysis consisted of evaluating several parameters, such as inheritance 137 138 patterns, variant location, variant type (e.g., missense variants, splice site alterations, and 139 coding in-frame and nonframeshift indels), and variant frequency in population databases 140 such as gnomAD [https://gnomad.broadinstitute.org/]. Published reports of pathogenicity 141 and data from resources such as ClinVar [https://www.ncbi.nlm.nih.gov/clinvar/] were also 142 integrated. Pathogenicity predictions were performed using REVEL 143 [https://sites.google.com/site/revelgenomics. The gathered data were synthesized, and 144 variant classifications were determined using tools such as Varsome [https://varsome.com/] 145 and the Franklin Platform [https://franklin2.genoox.com/]. All the implemented databases, 146 tools and platforms were last accessed on 26.08.2024. [9]

147 Classification of variants

Variants were classified following the international ACMG-AMP guidelines [9]. The variant
NM_000152.5(*GAA*):c.271G>A, p.Asp91Asn, was assessed by applying *the* latest specific
guidelines from the Lysosomal Diseases Expert Panel (ClinGen LSD VCEP)
[https://clinicalgenome.org/affiliation/50009/] [14].

152 Results

153 Case 1: Clinical characteristics

The proband is the Cangrande della Scala (1291–1329 CE), a prominent figure from medieval 154 155 Italy known for his military and political accomplishments as the Lord of Verona. Due to the 156 destruction of the Scaliger family archives, the little we know about his health relies on 157 limited, ambiguous and, often, biased historical accounts. Contemporary sources indicate 158 that Cangrande suffered from several bouts of illness throughout his life. At the age of 23, he 159 presented a significant ailment that temporarily hindered his mobility. Later, at the age of 34, 160 he suffered from a severe and prolonged illness that was nearly fatal. Last, at the age of 38 161 years, he died from an illness vaguely described as *fluxum*, often interpreted as vomiting or 162 diarrhea. The accounts report that his last three days were marked by fever and 163 gastrointestinal symptoms. In 2004, an autopsy and a toxicology analysis performed on 164 Cangrande's mummified remains detected toxic doses of digitalis in his preserved organs, 165 which could be interpreted as poisoning or as a remedy for a cardiac condition. Overall, the above mentioned accounts are nonspecific and could be due to various conditions, ranging 166 from 167 battle injuries to infectious or chronic diseases. 168 Case 2: Clinical characteristics

The proband (II.1) had an onset in their 30s, with proximal weakness, predominantly in the lower limbs. Physical examination revealed 4/5 strength in the flexors and extensors of the neck, deltoids, biceps, triceps, psoas, quadriceps, gluteal muscles, hamstrings, and abdominal

muscles, with an inability to stand up. Reflexes were preserved. The patient reported swallowing difficulties. Muscle MRI revealed moderate atrophy with fatty infiltration in the gluteal and hamstring muscles. During their last evaluation, in their 70s, the patient exhibited 4/5 weakness in the deltoids, biceps, eyelids, quadriceps, psoas, and gluteal muscles. The alpha-glucosidase activity was 1.68 μmol/L/h, which was slightly lower than the reference value.

The patient's brother (II.2) exhibited a similar clinical picture, but he declined to participate in
the genetic testing (Figure 1A). The proband reported that her deceased parents showed no
visible signs of muscle weakness compatible with LOPD.

181 Classification of the NM_000152.5(GAA):c.271G>A, p.Asp91Asn variant

182 The GAA2 variant was found in a heterozygous state together with the pathogenic 183 NM 000152.5(GAA):c.1465G>A in the mummy from case 1 and in a homozygous state in case 184 2. Therefore, to reclassify the variant and provide genetic diagnosis, evidence was gathered 185 from various literature reviews and databases and rigorously analyzed. A summary of the 186 applied criteria is provided in Table 1. Notably, there is evidence indicating that the GAA2 187 variant affects splicing and *in vitro* enzymatic activity; however, this effect was proven to be 188 compensated by an increase in substrate concentration [13,19,20]. Therefore, neither the PS3 189 nor the BS3 criteria were applied. Additionally, BA1 was implemented given the variant's high 190 allele frequency in general population databases, a criterion that could not be excluded owing 191 to the lack of strong and solid evidence supporting its pathogenicity. Overall, the GAA2 variant 192 meets the criterion of being classified as benign for Pompe disease. Moreover, the correlation 193 between the presence of GAA2 and decreased alpha-glucosidase activity indicated that the 194 variant was a pseudodeficiency allele.

11

195 Classification of NM 004643.4 (PABPN1):c.18 23dup the variant 196 To provide a genetic diagnosis for patient 2 and due to the reclassification of the GAA2 variant 197 as benign, the WES analysis was expanded to other genes with clinical features overlapping 198 with LOPD. This screening revealed a heterozygous 6-nucleotide duplication in PABPN1 199 [NM 004643.4 (PABPN1):c.18 23dup]. This gene is associated with autosomal dominant 200 oculopharyngeal muscular dystrophy (OPMD; OMIM #602279), a disease caused by the 201 abnormal expansion of GCN trinucleotide repeats. The detected duplication resulted in an 202 expansion of the GCG triplet, leading to the addition of two alanine residues in the polyalanine 203 tract region (Figure 1). Evidence was gathered to classify the variant, and a score of 10 points 204 was achieved, reaching the pathogenic classification. A summary of the applied criteria is 205 provided in Table 2. Therefore, the proband was diagnosed with OPMD instead of the 206 suspected late-onset Pompe disease.

207 Discussion

For several years, the interpretation of the NM_000152.5(GAA):c.271G>A pseudodeficiency 208 209 allele has led to controversy among the scientific community due to its inaccurate in vitro 210 enzymatic activity [13,19–21]. Iadarola et al. (2021) further contributed to this confusion by 211 classifying the variant as pathogenic in a renowned journal in 2021 [15]. Furthermore, the 212 authors concluded that Cangrande della Scala suffered from LOPD; thus, he was the first 213 known case of this disease. These authors based their conclusions on the interpretation of 214 insufficient, imprecise and biased clinical data obtained from limited reliable sources over 7 215 centuries of age, together with the finding of two variants in the GAA gene (the 216 pseudodeficiency allele c.271G>A and a pathogenic variant c.1465G>A) in the mummified 217 sample. According to the current diagnostic guidelines for Pompe disease, which requires

218 both a decreased GAA enzymatic activity and two pathogenic GAA in trans variants, there are 219 several reasons why it is incorrect to assert that Cangrande had LOPD [10,22,23]. First, due to 220 the nature of the sample, it was not possible to measure the alpha-glucosidase activity. 221 Second, the authors did not prove with 100% certainty that the GAA changes were in trans. 222 Third and most importantly, based on the evidence available to date Cangrande, the mummy, 223 carried a single heterozygous pathogenic GAA variant, and the NM 000152.5(GAA):c.271G>A, 224 p.Asp91Asn, which is interpreted as benign for Pompe disease. Therefore, based on the 225 available historical data and autopsy findings, there is no clear or compelling evidence 226 sufficient to determine that Cangrande della Scala suffered from Pompe disease or any other 227 specific lysosomal storage disorder. The existing medical records and interpretations remain 228 vague and insufficient to draw definitive conclusions about underlying health issues. 229 The most important outcome from the reanalysis of this case is that, in collaboration with the 230 ClinGen Lysosomal Storage Disorders Expert Panel, the variant was successfully reclassified as 231 benign in ClinVar [https://www.ncbi.nlm.nih.gov/clinvar/variation/4020/].

232 In the second case, the patient, with clinical suspicion of LOPD, was genetically diagnosed with 233 OPMD owing to a pathogenic heterozygous variant in polyadenylate-binding protein nuclear 234 1 (PABPN1). The protein encoded by PABPN1 plays a crucial role in adding poly(A) tails to the 235 3' ends of pre-messenger RNAs during messenger RNA maturation in the nucleus. Moreover, 236 PABPN1 is involved in regulating poly(A) tail length and mRNA stability, as well as in mediating 237 mRNA transport from the nucleus to the cytoplasm and degradation [24]. OPMD is a rare, 238 late-onset autosomal dominant neuromuscular disorder characterized by proximal muscle 239 weakness, ptosis, and difficulty in swallowing [25]. The molecular mechanism of this 240 pathology is associated with an abnormal expansion of the GCN trinucleotide repeat

(between 11 and 18 repeats) in the *PABPN1* gene [26]. The pathophysiology of OPMD involves
repeat expansions in the *PABPN1* gene, resulting in the production of a mutated protein that
forms toxic aggregates in muscles, disrupting RNA processing and causing progressive muscle
degeneration [26].

245 Despite being distinct disorders, OPMD and Pompe disease present significant clinical overlap 246 [1]. These patients share clinical features such as progressive muscle weakness, dysphagia, 247 and, to a lesser extent, ptosis and proximal muscle involvement. However, Pompe disease is 248 distinguished by a more significant respiratory engagement and a more generalized muscle 249 weakness [1,27]. Overall, Case 2 illustrates the importance of considering a differential 250 diagnosis when faced with ambiguous enzymatic and genetic results.

251 On the one hand, this case allowed us to confirm that the patient's decreased in vitro acid 252 alpha-glucosidase enzymatic activity was due to the pseudodeficiency variant in 253 homozygosity and that it was not associated with the patient's final diagnosis which was 254 OPMD [10]. Hence, caution should be taken when considering these cases, as 255 pseudodeficiency alleles can mask the underlying cause of the disease if they are not carefully 256 evaluated using 4-MUG as a substrate [10]. Moreover, if the patient in case 2 had been 257 diagnosed with LOPD, she would have undergone unnecessary enzyme replacement therapy, 258 while the OPMD would have remained undetected. On the other hand, patient 2 serves as an 259 example exome analysis scope, as it permits *in silico* panel customization to find alterations 260 in genes that are not the primary clinical suspicion.

In summary, we have established a global consensus on the classification of the NM_000152.5(*GAA*):c.271G>A, p.Asp91Asn variant as benign considering all the available evidence to date, analyzed in accordance with the latest international guidelines. The

264 experience gained reaffirms that the accurate diagnosis of rare genetic diseases requires 265 adherence to international consensus guidelines and a thorough evaluation of genetic variants. This helps prevent diagnostic errors and improves the quality of medical care. 266 267 Furthermore, precise genetic diagnosis and strict variant curation are crucial for guiding 268 therapeutic decisions and avoiding inappropriate treatments that may arise from incorrect 269 diagnoses. Ensuring that variants are accurately classified allows for better-informed clinical 270 choices, ultimately benefiting patient outcomes by tailoring therapy to the correct underlying 271 condition. Finally, sharing data with reliable results is vital for future reinterpretations of 272 variants, so we encourage the scientific and medical community to contribute to this mission.

273 Data availability statement

274 The genetic variant data that support the findings of this study are openly available in LOVD3

275 database: GAA and PABPN1 variants submission link:

276 https://databases.lovd.nl/shared/individuals/00453583.

277 References

Cupler EJ, Berger KI, Leshner RT, Wolfe GI, Han JJ, Barohn RJ, et al. Consensus treatment
 recommendations for late-onset Pompe disease. Muscle Nerve. 2012;45: 319–333.

Taglia A, Picillo E, D'Ambrosio P, Cecio MR, Viggiano E, Politano L. Genetic counseling in
 Pompe disease. Acta Myol. 2011;30: 179–181.

de Faria DOS, 't Groen SLMI, Hoogeveen-Westerveld M, Nino MY, van der Ploeg AT,
 Bergsma AJ, et al. Update of the Pompe variant database for the prediction of clinical
 phenotypes: Novel disease-associated variants, common sequence variants, and results
 from newborn screening. Hum Mutat. 2021;42: 119–134.

Peruzzo P, Pavan E, Dardis A. Molecular genetics of Pompe disease: a comprehensive
 overview. Ann Transl Med. 2019;7: 278.

Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, et al. Pompe disease diagnosis
 and management guideline. Genet Med. 2006;8: 267–288.

290 6. Kroos M, Hoogeveen-Westerveld M, van der Ploeg A, Reuser AJJ. The genotype-

- phenotype correlation in Pompe disease. Am J Med Genet C Semin Med Genet.
 2012;160C: 59–68.
- Thuriot F, Gravel E, Hodson K, Ganopolsky J, Rakic B, Waters PJ, et al. Molecular Diagnosis
 of Pompe Disease in the Genomic Era: Correlation with Acid Alpha-Glucosidase Activity
 in Dried Blood Spots. J Clin Med Res. 2021;10. doi:10.3390/jcm10173868
- Taverna S, Cammarata G, Colomba P, Sciarrino S, Zizzo C, Francofonte D, et al. Pompe
 disease: pathogenesis, molecular genetics and diagnosis. Aging . 2020;12: 15856–15874.
- Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines
 for the interpretation of sequence variants: a joint consensus recommendation of the
 American College of Medical Genetics and Genomics and the Association for Molecular
 Pathology. Genet Med. 2015;17: 405–424.
- Niño MY, Wijgerde M, de Faria DOS, Hoogeveen-Westerveld M, Bergsma AJ, Broeders
 M, et al. Enzymatic diagnosis of Pompe disease: lessons from 28 years of experience. Eur
 J Hum Genet. 2021;29: 434–446.
- 305 11. Dalmia S, Sharma R, Ramaswami U, Hughes D, Jahnke N, Cole D, et al. Enzyme
 306 replacement therapy for late-onset Pompe disease. Cochrane Database Syst Rev.
 307 2023;12: CD012993.
- van der Beek NAME, Hagemans MLC, van der Ploeg AT, Reuser AJJ, van Doorn PA. Pompe
 disease (glycogen storage disease type II): clinical features and enzyme replacement
 therapy. Acta Neurol Belg. 2006;106: 82–86.
- Swallow DM, Kroos M, Van der Ploeg AT, Griffiths B, Islam I, Marenah CB, et al. An
 investigation of the properties and possible clinical significance of the lysosomal alpha glucosidase GAA*2 allele. Ann Hum Genet. 1989;53: 177–184.
- 314 14. Goldstein JL, McGlaughon J, Kanavy D, Goomber S, Pan Y, Deml B, et al. Variant
 315 Classification for Pompe disease; ACMG/AMP specifications from the ClinGen Lysosomal
 316 Diseases Variant Curation Expert Panel. Mol Genet Metab. 2023;140: 107715.
- 15. Iadarola B, Lavezzari D, Modi A, Degli Esposti C, Beltrami C, Rossato M, et al. Wholeexome sequencing of the mummified remains of Cangrande della Scala (1291-1329 CE)
 indicates the first known case of late-onset Pompe disease. Sci Rep. 2021;11: 21070.
- 320 16. Medical Research Council. Aids to the Examination of the Peripheral Nervous System.321 1976.
- Murray MG, Thompson WF. Rapid isolation of high molecular weight plant DNA. Nucleic
 Acids Res. 1980;8: 4321–4325.
- 18. Benarroch L, Bonne G, Rivier F, Hamroun D. The 2024 version of the gene table of neuromuscular disorders (nuclear genome). Neuromuscul Disord. 2024;34: 126–170.
- 326 19. Martiniuk F, Bodkin M, Tzall S, Hirschhorn R. Identification of the base-pair substitution

- responsible for a human acid alpha glucosidase allele with lower "affinity" for glycogen
 (GAA 2) and transient gene expression in deficient cells. Am J Hum Genet. 1990;47: 440–
 445.
- Goina E, Musco L, Dardis A, Buratti E. Assessment of the functional impact on the pre mRNA splicing process of 28 nucleotide variants associated with Pompe disease in GAA
 exon 2 and their recovery using antisense technology. Hum Mutat. 2019;40: 2121–2130.
- 21. Löscher WN, Huemer M, Stulnig TM, Simschitz P, Iglseder S, Eggers C, et al. Pompe
 disease in Austria: clinical, genetic and epidemiological aspects. J Neurol. 2018;265: 159–
 164.
- 336 22. Musumeci O, Toscano A. Diagnostic tools in late onset Pompe disease (LOPD). Ann Transl
 337 Med. 2019;7: 286.
- van der Ploeg AT, Kruijshaar ME, Toscano A, Laforêt P, Angelini C, Lachmann RH, et al.
 European consensus for starting and stopping enzyme replacement therapy in adult
 patients with Pompe disease: a 10-year experience. Eur J Neurol. 2017;24: 768–e31.
- 341 24. Kühn U, Wahle E. Structure and function of poly(A) binding proteins. Biochim Biophys
 342 Acta. 2004;1678: 67–84.
- Robinson DO, Wills AJ, Hammans SR, Read SP, Sillibourne J. Oculopharyngeal muscular
 dystrophy: a point mutation which mimics the effect of the PABPN1 gene triplet repeat
 expansion mutation. J Med Genet. 2006;43: e23.
- 346 26. Brais B, Bouchard JP, Xie YG, Rochefort DL, Chrétien N, Tomé FM, et al. Short GCG
 347 expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Genet.
 348 1998;18: 164–167.
- Toscano A, Montagnese F, Musumeci O. Early is better? A new algorithm for early
 diagnosis in late onset Pompe disease (LOPD). Acta Myol. 2013;32: 78–81.
- 351 Acknowledgments
- 352 We would like to thank the Lysosomal Diseases Expert Panel (ClinGen LSD VCEP)
- 353 [https://clinicalgenome.org/affiliation/50009/] for the recommendations on classifying the
- 354 NM_000152.5(GAA):c.271G>A, p.Asp91Asn variant. We thank Dr. Eleonora Katz for reviewing
- and editing the English writing of this work.

356 Author Contribution Statement

- 357 Conceived and designed the methodology: F.G. and P.I.B. Analysis of clinical history and
- 358 medical aspects: F.G., G.C. and C.L.M. Analyzed patient samples: F.G. and M.C. Analyzed and

17

- discussed the data: F.G., P.I.B., G.C., C.L.M., V.D., L.L. and M.C. Wrote the paper: F.G., P.I.B.,
- 360 V.D. and M.C. All the authors reviewed the manuscript.

361 Ethical Approval

- 362 The study was conducted in accordance with the Declaration of Helsinki and approved by the
- 363 Institutional Review Board (or Ethics Committee) of Facultad de Farmacia y Bioquímica
- 364 (06122023-167) and by the Institutional Review Board (or Ethics Committee) of Hospital de
- 365 Clínicas "José de San Martín" (1218-23).

366 Competing Interests

- 367 The authors declare no competing interests.
- 368
- 369
- 370
- 371

18

372 Figure 1



373

Figure 1: Case 2 presentation. A: Pedigree of the affected family. The proband is indicated by an arrow. N/A: Not available. WT: wild-type allele. B: Visualization of the proband's sequencing reads via IGV, demonstrating the expansion of the GCG triplet in exon 1 of the *PABPN*1 gene, resulting in two additional alanines in the protein.

19

379	Table 1:	Summary	of	the	rules	applied	for	the	interpretation	of	the	variant
380	NM_00015	52.5(<i>GAA</i>):c	.271	G>A (p.Asp9	1Asn)						

Applied	Explanation	Reference/Evidence						
Rules								
BA1	Allele frequency is 3.29%	[gnomad.broadinstitute.org]						
(Stand	(4183/127102, 70 homozygous							
alone)	in non-Finnish European							
	population) in GnomAD v2.1.1							
BP2	Observed in Cis with a	PMID: 16838077, 33073003, 27189384 <u>(28–30)</u>						
(Supporting)	pathogenic variant in patients							
	with POMPE.							
	REVEL score of 0.206 which is	Bouch and SpliceAl predictor scores were						
(Supporting)	helow the threshold of 0.5 for	determined with the Variant Effect Predictor tool						
(Supporting)	the pathogenicity effect. The	[https://www.ensembl.org/Tools/VEP]						
	SpliceAI splicing predictor							
	predicts that the variant has no							
	impact on splicing.							
BS2 (Strong)	Observed in a healthy adult	[gnomad.broadinstitute.org]						
	individual for a recessive							
	(homozygous), dominant							
	(heterozygous), or X-linked							
	(nemizygous) disorder, with full							
	age.							
	-0							

381

383	Table 2:	Summary	of the	rules	applied	for	the	interpretation	of	the	variant
384	PABPN1(NM_004643.4):c.18_23dup (p.Ala10_Ala11dup)										

Applied	Explanation	Reference/Evidence
Rules		
PM1	Located in a critical and	11 reported pathogenic or probably pathogenic
(Moderate)	well-established	variants were found in a 25 bp region surrounding
	mutational hot spot and/or	this variant in exon 1 without any benign variants.
	functional domain (e.g.,	
	active site of an enzyme)	
	without benign variation.	
PS1 (Strong)	Same amino acid change as	High-certainty ClinVar pathogenic variants. Variant
	a variant previously	ID: 2437738; Chr14:23321487:G>GGCGGA
	reported as pathogenic	
PS4	The prevalence of the	Reported in ClinVar in cases of affected
(Moderate)	variant in affected	SCV000330133: "The c.18_23dup pathogenic variant
	individuals is significantly	in the PABPN1 gene has been reported previously in
	higher compared to that in	individuals with oculopharyngeal muscular dystrophy
	controls.	in four families (Brais et al. 1998)"(<u>26)</u>
		SCV001248587: "Reported in affected case by
		submitting lab"
PM2	Extremely low frequency in	[gnomad.broadinstitute.org]
(Supporting)	gnomAd population	
	databases	
PP4	Patient's phenotype or	The c.18_23dup pathogenic variant in the PABPN1
(Supporting)	family history is highly	gene has been reported previously in individuals with
	specific for a disease with a	oculopharyngeal muscular dystrophy in four families
	single genetic etiology.	<u>(26)</u>